When to start antiretroviral therapy and what to start with - A European perspective

Current Infectious Disease Reports

Volumn 5, Issue 4, 2003, Pages 349-357

  Wit, Ferdinand W N M ^a   Reiss, Peter ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIPRURITIC AGENT; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CORTICOSTEROID; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANAPHYLAXIS; ANEMIA; ATTENTION DEFICIT DISORDER; CARDIOMYOPATHY; CLINICAL TRIAL; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; FATIGUE; FATTY LIVER; GASTROINTESTINAL DISEASE; GILBERT DISEASE; GLUCOSE INTOLERANCE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INDIVIDUALIZATION; INSOMNIA; INSULIN RESISTANCE; KIDNEY TUBULE ACIDOSIS; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; METABOLIC DISORDER; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; PANCREATITIS; PATIENT COMPLIANCE; POLYNEUROPATHY; REVIEW; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TERATOGENICITY; TIME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING; VOMITING;

EID: 3142664716     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0013-y     Document Type: Review

References (68)

1. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146-154.
2. Larder BA, Kellam P, Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993, 365:451-453.
3. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
4. Preston BD, Poiesz BJ, Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988,242:1168-1171.
5. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
6. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.
7. Staszewski S, Keiser P, Montaner J, et al.: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001, 285:1155-1163.
8. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
9. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997, 349:1086-1092.
10. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
11. Montaner JS, Hogg R, Raboud J, Harrigan R, O'Shaughnessy M: Antiretroviral treatment in 1998. Lancet 1998, 352:1919-1922.
12. Moyle GJ, Gazzard BG, Cooper DA, Gatell J: Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 1998, 55:383-404.
13. Carpenter CC, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
14. Ledergerber B, Egger M, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999, 282:2220-2226.
15. Hogg RS, Yip B, Kully C, et al.: Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999, 160:659-665.
16. Wit FW, van Leeuwen R, Weverling GJ, et al.: Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
17. Weverling GJ, Mocroft A, Ledergerber B, et al.: Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999, 353:1293-1298.
18. Ledergerber B, Mocroft A, Reiss P, et al.: Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001, 344:168-174.
19. Kirk O, Reiss P, Uberti-Foppa C, et al.: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137:239-250.
20. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
21. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
22. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
23. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997, 94:13193-13197.
24. Zhang H, Dornadula C, Beumont M, et al.: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998, 339:1803-1809.
25. Schuetz JD, Connelly MC, Sun D, et al.: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999, 5:1048-1051.
26. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999, 96:10958-10961.
27. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
28. Fatkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-116.
29. Bonfanti P, Capetti A, Di Mattei P, et al.: Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients. AIDS 1998, 12:1111.
30. Kaufmann D, Pantaleo G, Sudre P, Telenti A: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723-724.
31. Belec L, Piketty C, Si-Mohamed A, et al.: High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000, 181:1808-1812.
32. Deeks SG, Barbour JD, Martin JN, et al.: Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000, 181:946-953.
33. Borleffs JC, Danner SA, Lange JM, van Everdingen JJ: CBO guidelines antiretroviral therapy in the Netherlands. Ned Tijdschr Geneeskd 2001, 145:1585-1589.
34. Sterling TR, Chaisson RE, Moore RD: HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
35. Boyle BA: Issues in antiretroviral therapy: when to start? AIDS Read 2001, 11:66-70.
36. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
37. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002, 51:1-55.
38. Hogg RS, Yip B, Chan KJ, et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
39. Phillips AN, Staszewski S, Weber R, et al.: HIV viral load response to antiretroviral therapy according to the baseline cd4 cell count and viral load. JAMA 2001, 286:2560-2567.
40. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
41. Grabar S, Le Moing V, Goujard C, et al.: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401-410.
42. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
43. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
44. Brinkman K, ter Hofstede HJ, Burger DM, et al.: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
45. Brinkman K, Smeitink JA, Romijn JA, Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112-1115.
46. Clay PG, Rathbun RC, Slater LN: Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother 2000, 34:247-249.
47. Wit FW, Wood R, Horban A, et al.: Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001, 15:2423-2429.
48. Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31.
49. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
50. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
51. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.
52. Hurst M, Faulds D: Lopinavir. Drugs 2000, 60:1371-1379.
53. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996, 124:1019-1030.
54. Montaner JS, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930-937.
55. van Leth F: Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract 176]. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston. February 10-14, 2003.
56. Staszewski S, Katlama C, Harrer T, et al.: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998, 12:F197-202.
57. van Leeuwen R, Katlama C, Murphy R, et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003, 17:987-999.
58. Moyle G: Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001, 11:87-98.
59. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
60. Prins JM, Jurriaans S, van Praag RM, et al.: Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405-2410.
61. Weverling GJ, Lange JM, Jurriaans S, et al.: Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-122.
62. van Praag RM, Wit FW, Jurriaans S, de Wolf F, et al.: Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002, 16:719-725.
63. Dybul M, Chun TW, Yoder C, et al.: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001, 98:15161-15166.
64. Neumann AU, Tubiana R, Calvez V, et al.: HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999, 13:677-683.
65. Reijers MH, Weverling GJ, Jurriaans S, et al.: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
66. Hall DB, Montaner JG, Reiss P, et al.: Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998, 12:F41-44.
67. Martinez E, Conget I, Lozano L, et al.: Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805-810.
68. Barreiro P, Soriano V, Blanco F, et al.: Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000, 14:807-812.